This technical guidance describes the methods and implementation considerations to monitor the prevalence of HIV drug resistance among PrEP users diagnosed with HIV through a cross-sectional survey. The outcomes of the survey will be used to inform the selection of maximally effective first-line combination antiretroviral therapy for PrEP users who acquire HIV.
This technical guidance describes the methods and implementation considerations to monitor the prevalence of HIV drug resistance among PrEP users diagnosed with HIV through a cross-sectional survey. The outcomes of the survey will be used to inform the selection of maximally effective first-line combination antiretroviral therapy for PrEP users who acquire HIV.